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Abstract
Background: Comorbid diabetes is common in heart failure and associated with increased hospitalization and
mortality. Nonetheless, the association between glycemic control and outcomes among patients with heart
failure and diabetes remains poorly characterized, particularly among low income and minority patients.
Methods: We performed a retrospective cohort study of outpatients with heart failure and diabetes in the New
York City Health and Hospitals Corporation, the largest municipal health care system in the United States. Cox
proportional hazard models were used to measure the association between HbA1c levels and outcomes of all-cause
hospitalization, heart failure hospitalization, and mortality.
Results: Of 4723 patients with heart failure and diabetes, 42.6 % were black, 30.5 % were Hispanic/Latino, 31.4 % were
Medicaid beneficiaries and 22.9 % were uninsured. As compared to patients with an HbA1c of 8.0–8.9 %, patients with
an HbA1c of <6.5, 6.5–6.9, 7.0–7.9, and ≥9.0 % had an adjusted hazard ratio (aHR) (95 % CI) for all-cause hospitalization
of 1.03 (0.90–1.17), 1.05 (0.91–1.22), 1.03 (0.90–1.17), and 1.13 (1.00–1.28), respectively. An HbA1c ≥ 9.0 % was
also associated with an increased risk of heart failure hospitalization (aHR 1.33; 95 % CI 1.11–1.59) and a non-significant
increased risk in mortality (aHR 1.20; 95 % CI 0.99–1.45) when compared to HbA1c of 8.0–8.9 %.
Conclusions: Among a cohort of primarily minority and low income patients with heart failure and diabetes,
an increased risk of hospitalization was observed only for an HbA1c greater than 9 %.
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Background
Heart failure and diabetes are two chronic diseases that
commonly coexist. Among patients with heart failure,
the prevalence of diabetes is as high as 40 % [1–3] and is
increasing [4]. The high rate of diabetes in heart failure
holds clinical significance as diabetes has been associated
with worse outcomes in heart failure. For instance, in a
meta-analysis of 17 studies, patients with heart failure
and diabetes were found to have a 28 % increase in mor-
tality and a 36 % increase in hospitalizations as com-
pared to patients with heart failure but no diabetes [5].
The relationship between heart failure and diabetes may
be magnified among high-risk populations such as racial
minorities, individuals of low socioeconomic status, and
the uninsured [6–10].
Despite the increased risk of poor outcomes among
patients with heart failure and diabetes, the optimal
hemoglobin A1c (HbA1c) level for patients with heart
failure and diabetes remains uncertain. Due to lack of
existing data, heart failure guidelines do not specifically
address the intensity of glycemic control among individ-
uals with heart failure [11], and the American Diabetes
Association (ADA) guidelines do not provide a specific
treatment target [12]. Although elevated levels of HbA1c
have been associated with increased risk for heart failure
related hospitalizations [13–16], intervention trials in pa-
tients with Type 2 diabetes have failed to show benefit
with tight glycemic control and some studies have even
suggested harm [17–19]. Additionally, tight glycemic
control could predispose to volume retention in heart
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failure by decreasing the osmotic diuretic effect of gluco-
semia [20]. Given the potential side effects of both tight
and loose glycemic control among heart failure patients,
moderate glycemic control would seem appropriate. In-
deed, a study of primarily male patients from Veterans
Affairs (VA) medical centers demonstrated a U-shaped
relationship between HbA1c and mortality, with the
lowest risk observed for patients with an HbA1c be-
tween 7.1 and 7.8 % [21]. Conversely, two studies from a
single academic advanced heart failure clinic found low
[22, 23] HbA1c values to be associated with increased
risk of mortality, while a high HbA1c was associated
with mortality for heart failure patients enrolled in the
CHARM study [24]. Notably, these prior studies focused
on select patient populations such as those who were
fully insured or who agreed to participate in a clinical
trial [21–24]. As a result, the optimal HbA1c target for
heart failure patients with diabetes remains uncertain,
especially for members of racial and ethnic minorities
not well represented in previous studies [21–24].
The purpose of this study was to evaluate the asso-
ciation of HbA1c with all-cause hospitalization among
patients with heart failure and diabetes in a hospital
system serving a diverse, urban, and primarily low-income
population. We hypothesized that hospitalization rates
would vary with level of HbA1c with a U-shaped relation-
ship, such that moderate glycemic control would be asso-
ciated with reduced all-cause hospitalization, heart failure
hospitalization, and mortality.
Methods
We performed a non-concurrent cohort study of pa-
tients in the New York City Health and Hospitals
Corporation (HHC), the largest municipal health care
system in the United States. The corporation serves
approximately 1.4 million people, of whom nearly
500,000 are uninsured, and includes 11 hospitals, six
diagnostic and treatment centers, four long term care
centers, and one hundred community health centers
[25]. The primary data source for the study was the
HHC data warehouse which contains data from the
electronic health records (EHRs) from each of the
hospitals and includes demographic information, clin-
ical measures, problem lists, laboratory tests and re-
sults, and medication orders. Patient data from HHC
was matched to two New York State data registries to
obtain outcomes data: the New York State Vital
Statistics and the New York Statewide Planning and
Research Cooperative System (SPARCS). Vital statis-
tics maintains records of deaths in the state, while
SPARCS contains all acute care admissions for non-
federal hospitals in the state.
We included patients with heart failure and diabetes
who had an outpatient clinic visit in HHC between 1/1/
2007 and 12/31/2010. Diagnoses were based on Inter-
national Classification of Diseases, Clinical Modification
(ICD-9-CM) codes of 428 and 250, respectively, in the
problem list [3, 26]. Additional inclusion criteria were
age 18 years and older and measurement of an HbA1c
either on or up to 90 days prior to the clinic visit. For
patients with multiple encounters, we only included the
first visit for which inclusion criteria were met.
The primary outcome was all-cause hospitalization.
Secondary outcomes were heart failure hospitalization
and mortality. Heart failure hospitalization was based on
a principal diagnosis of heart failure using standard
ICD-9-CM codes [3, 27].
The primary exposure was HbA1c, which was cate-
gorized into the following clinically relevant categories:
<6.5, 6.5–6.9, 7.0–7.9, 8.0–8.9, and ≥9.0 %. Other patient
characteristics included age, gender, race, ethnicity, pri-
mary payer, prior utilization, comorbidities, diabetes
severity, systolic blood pressure, pulse, creatinine,
hemoglobin, active medications, prior utilization, and
HHC facility of the clinic visit. Characteristics were
assessed at time of clinic visit with the exception of
laboratory values which, if unavailable at time of clin-
ical visit, could be included if assessed up to 90 days
prior to the clinic visit. In the data warehouse, race
was self-reported as a single category and included
responses of “Black or African American”, “Hispanic
Black”, and “Hispanic or Latino”. From this informa-
tion, we created a race variable that was categorized
as black or other and an ethnicity variable which was
categorized as Hispanic/Latino and other. Comorbidi-
ties were based on standard algorithms [28]. Diabetes
severity was assessed using the diabetes complication
severity index, a validated index of complications of
diabetes that has been associated with hospitalization
and mortality [29]. Medication utilization was based on an
active prescription and included the following medication
classes: loop diuretic, angiotensin converting enzyme
(ACE) inhibitor or angiotensin receptor blocker (ARB),
beta blocker, insulin, metformin, and sulfonylurea. Prior
utilization included hospitalization in the prior 90 days
and number of hospitalizations, emergency department
visits, and clinic visits in the prior year.
Follow up time was defined from time of clinic visit.
Patients were followed to the time of death or December
31, 2010; patients who were unable to be accurately
matched to mortality data (n = 117) were censored on
their last date of service.
Statistical analysis
Differences in frequency of outcomes among all HbA1c
groups were compared using Pearson chi-squared tests.
We plotted Kaplan-Meier curves for hospitalization;
curves were compared using the log-rank test. Cox
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proportional hazard models were developed to deter-
mine the relative association of HbA1c category with
the primary outcome variable, all-cause hospitalization.
The proportionality assumption was evaluated graphic-
ally using the -log(−log(survival function)) plot and sta-
tistically using the Schoenfeld residuals. We developed
adjusted Cox models incorporating baseline patient
characteristics as well as shared-frailty to account for
clustering within each HHC site [30]. Covariates
included in the adjusted model were age, sex, race, eth-
nicity, insurance, comorbidities, blood pressure, heart
rate, creatinine, hemoglobin, medications, and prior
utilization. Similar models were developed for the sec-
ondary outcomes. We performed a sensitivity analysis
in which we developed similar models with the primary
independent variable of HbA1c categorized as <6.5,
6.5–6.9, 7.0–7.9, 8.0–8.9, 9.0–9.9, 10.0–11.9, and ≥12.0 %.
Statistical significance was pre-specified with an alpha
level of 0.05 (two-tailed). Statistical analyses were per-
formed using Stata 13 (StataCorp, College Station, TX).
This study was approved by the New York University
School of Medicine Institutional Review Board.
Results
Of the 4723 patients with heart failure and diabetes in-
cluded in the study, the median age was 64 years, 42.6 %
were black, and 30.5 % were Hispanic or Latino. At the
time of clinic visit, 31.4 % of patients were Medicaid
beneficiaries and 22.9 % of patients had no insurance.
The mean HbA1c (SD) for the cohort was 8.2 (2.4).
The distribution of HbA1c categories of <6.5, 6.5–6.9,
7.0–7.9, 8.0–8.9, and ≥9.0 % was: 21.8, 12.7, 22.6, 15.0,
and 28.0 %, respectively. Patients with high HbA1c were
younger and had high rates of Medicaid insurance when
compared to patients with low HbA1c (Table 1). Patients
in the lowest HbA1c group were most likely to be black
and had the highest prevalence of kidney disease.
Patients with higher HbA1c had higher rates of insulin
use, while metformin was used most frequently among
patients with HbA1c of 6.5–6.9 %. HbA1c appeared to
be inversely correlated with number of outpatient encoun-
ters, as patients in the lowest two HbA1c groups had the
highest average number of clinic visits. (Table 1).
For the primary outcome of all-cause hospitalization,
patients were followed for a median (25th,75th percentile)
of 173 (46,452) days. During follow up, 67.0 % of
patients were hospitalized for any cause. Overall rates
of hospitalization were similar across HbA1c groups
(Table 2). Similarly, we found no difference in the
Kaplan Meier curves between HbA1c groups (see
Fig. 1). In unadjusted analysis, an HbA1c ≥9 % was
associated with increased risk of hospitalization, while
an HbA1c < 6.5 % was associated with risk of
hospitalization that did not reach statistical significance
(Table 3). After adjusting for covariates, the lowest
four categories of HbA1c (<6.5, 6.5–6.9, 7.0–7.9, and
8.0–8.9 %) were associated with similar hazard for
hospitalization (Table 3). Only patients with an HbA1c ≥
9.0 % had a significant increased risk for hospitalization
(adjusted HR 1.13; 95 % CI 1.00–1.28) when compared to
patients with HbA1c 8.0–8.9 % (Table 3).
The rate of heart failure hospitalizations was 35.3 %
for patients with HbA1c ≥ 9.0 % and 26.6–28.9 % for pa-
tients in categories with lower HbA1c (Table 2). After
adjustment for covariates, HbA1c ≥ 9.0 % was associated
with a hazard ratio for heart failure hospitalization of
1.33 (95 % CI 1.11–1.59) when compared to HbA1c 8.0–
8.9 %. Other categories of HbA1c did not significantly
differ in hazard ratio for heart failure hospitalization
when compared to the reference (Table 3).
The median (25th,75th percentile) follow up for mortal-
ity was 658 (289,1114) days. Over 30 % of patients with
HbA1c < 6.5 % died during the period while mortality
rates for higher HbA1c categories ranged from 23.7 to
26.8 % (Table 2). In unadjusted analysis, HbA1c < 6.5 %
was associated with a 32 % (95 % CI 10–60 %) increase
in hazard of death as compared to the reference group
of HbA1c 8.0–8.9 %. However, this association was at-
tenuated and was no longer significant after adjusting
for covariates (adjusted HR 1.16; 95 % CI 0.94–1.42;
Table 3). Similarly, an elevated HbA1c ≥ 9 % was associ-
ated with increased mortality in multivariable analysis
that did not reach statistical significance (adjusted HR
1.20; 95 % CI 0.99–1.45; Table 3). Indeed, in multivariate
adjustment, no level of HbA1c was statistically associ-
ated with increased mortality.
In sensitivity analysis in which we categorized
higher HbA1c values into 9.0–9.9 %, 10.0–11.9 %,
and ≥12 %, we found that hospitalization risk was
similar for each of these individual categories as when
grouped together (Appendix). An HbA1c over 12 %
was associated with a significant increase in mortality
as compared to HbA1c 8.0–8.9 %, with an adjusted
HR 1.33 (95 % CI 1.03–1.73). We found no significant as-
sociation between HbA1c of 9.0–9.9 % or 10.0–11.9 %
and mortality (Appendix).
Discussion
In this cohort of patients with heart failure and dia-
betes from a diverse, urban, and primarily low-
income hospital system, we found no difference in
risk of hospitalization or mortality for HbA1c levels
up to 8.9 %. Hospitalization risk only increased at
the highest HbA1c level; an HbA1c of 9.0 % or
higher was associated with a 13 % increase in the
relative hazard of all-cause hospitalization and a
33 % increase in the relative hazard of heart failure
hospitalization when compared to lower HbA1c
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values. Furthermore, we found the association be-
tween HbA1c and mortality to be significant only for
HbA1c levels above 12 %. These findings suggest
that, in this patient population, glycemic control is
not a strong predictor of outcomes in heart failure
and diabetes and risk of hospitalization begins to in-
crease only when HbA1c ≥ 9 %.
Consistent with our initial hypothesis, that both high
and low levels of HbA1c would be associated poor out-
comes, we found that an HbA1c < 6.5 % was associated
Table 1 Baseline characteristics of 4723 patients with heart failure and diabetes, by hemoglobin A1c (HbA1c) category
HbA1c range
<6.5 6.5–6.9 7–7.9 8–8.9 ≥9
(n = 1028) (n = 600) (n = 1065) (n = 706) (n = 1324)
Age, years 67.1 (12.9) 66.3 (12.4) 65.4 (12.0) 63.7 (11.7) 60.9 (11.5)
Female 53.6 52.0 55.6 52.3 49.2
Black Race 47.2 41.7 41.2 39.7 42.0
Hispanic/Latino Ethnicity 28.7 28.8 29.8 32.2 32.2
Insurance
Medicaid 28.2 31.2 30.6 33.3 33.5
Medicare 30.5 27.0 25.7 24.1 18.7
Private 4.1 4.5 3.4 4.7 4.6
Self-Pay 18.0 18.8 22.4 24.9 27.7
Other 19.3 18.5 17.9 13.0 15.4
Diabetes Severity Index 3.5 (1.7) 3.3 (1.7) 3.3 (1.6) 3.5 (1.7) 3.4 (1.7)
Comorbid Conditions
Myocardial Infarction 10.8 13.0 11.8 11.2 12.2
Peripheral Vascular Disease 14.7 11.7 13.3 15.0 11.7
Cerebrovascular Disease 17.8 15.5 16.9 13.2 10.7
Dementia 2.2 2.3 2.0 1.4 1.1
Chronic Pulmonary Disease 23.8 26.3 27.2 24.5 25.8
Rheumatic Disease 2.4 1.8 2.0 1.1 1.4
Liver Disease 7.5 5.2 4.0 3.7 4.8
Renal Disease 30.3 19.7 18.6 21.1 21.4
Malignancy or Tumor 8.6 10.0 6.4 6.5 5.8
Heart Rate, beats/min 74.8 (13.1) 75.2 (12.9) 76.3 (13.2) 77.6 (14.1) 78.2 (13.8)
Systolic Blood Pressure, mmHG 133.7 (22.4) 135.3 (23.0) 134.6 (22.2) 135.6 (23.4) 134.7 (22.9)
Creatinine, mg/dl 1.9 (1.8) 1.5 (1.2) 1.5 (1.2) 1.5 (1.3) 1.5 (1.3)
Hemoglobin, g/dl 11.6 (2.0) 12.0 (1.9) 12.0 (1.9) 12.1 (1.9) 12.2 (2.0)
ACE inhibitor or ARB 55.1 58.2 58.8 56.7 59.9
Beta-Blocker 36.7 34.8 37.5 35.6 34.5
Loop Diuretic 57.9 63.0 62.4 62.3 57.4
Insulin 21.7 25.2 35.8 50.9 62.3
Metformin 14.1 22.2 16.4 18.8 19.5
Sulfonylurea 9.0 11.7 12.4 9.8 10.6
Prior Utilization
Hospitalization in Prior 90 Days 54.3 45.3 52.8 53.8 58.9
Hospitalizations, Prior Year 1.5 (2.0) 1.2 (1.8) 1.4 (1.9) 1.4 (1.7) 1.5 (2.0)
ED Visits, Prior Year 0.6 (1.3) 0.5 (1.1) 0.6 (1.7) 0.5 (1.3) 0.6 (1.3)
Clinic Visits, Prior Year 6.9 (12.8) 7.3 (15.3) 6.6 (15.0) 5.3 (12.6) 5.5 (12.2)
Values are percentages or mean (standard deviation)
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with increased risk of mortality and a nonsignificant in-
crease in hospitalization in unadjusted analysis. How-
ever, a low HbA1c was also associated with a number of
factors associated with poor outcomes, including in-
creased age, cerebrovascular disease, and creatinine.
After adjusting for such confounders, a low HbA1c was
no longer associated with mortality or hospitalization.
Some studies have found that HbA1c may have a U- or
J-shaped relationship to outcomes [21, 31, 32], suggest-
ing there may also be a low threshold, below which risk
increases [32]. In this population of patients with heart
failure and diabetes, any risk associated with low HbA1c
was explained by other factors. These findings do not
support a low threshold effect in patients with heart fail-
ure and diabetes.
In our study, only levels of HbA1c of 9 % or higher
were associated with hospitalization and mortality. Con-
versely, observational studies in the general population
have suggested that mortality risk increases when the
HbA1c rises above 7 % [33, 34], the level recommended
by the ADA for most patients with diabetes [12]. Results
of four prior studies of the association between HbA1c
and health outcomes among patients with heart failure
and diabetes have been mixed. Two studies of patients
with advanced heart failure from the same single center
suggested that tighter glycemic control was associated
with increased mortality [22, 23]. Conversely, among a
subgroup of patients with heart failure and diabetes en-
rolled in the CHARM study, Gerstein and colleagues
found that a 1 % increase in HbA1c was associated with
an increased hazard ratio of 1.13 for heart failure
hospitalization and 1.11 for mortality [24]. Finally,
Aguilar and colleagues studied 5815 male patients in
the VA and found that an HbA1c of 7.1–7.8 % was as-
sociated with a hazard ratio for mortality of 1.31–1.45
as compared to both higher and lower values. However,
the authors found no significant association between
HbA1c and hospitalization [21].
While the studies by Gerstein [24] and Aguilar [21]
found higher HbA1c was associated with increased
risk of mortality, we found no statistical association
between HbA1c and mortality in our primary analysis.
The difference between our study and the prior stud-
ies is that we included a real-world patient population
Table 2 Frequency of outcome events of hospitalization, mortality, and heart failure hospitalization during follow up, by HbA1c
category
HbA1c range p
<6.5 (n = 1028) 6.5–6.9 (n = 600) 7–7.9 (n = 1065) 8–8.9 (n = 706) ≥9 (n = 1324)
Hospitalization 68.6 64.7 65.2 66.2 68.9 0.16
Heart Failure Hospitalization 26.6 27.5 28.9 28.8 35.3 <0.001
Mortality 30.5 25.5 24.1 23.7 26.8 <0.01
Fig. 1 Kaplan Meier curves for hospitalization free survival by HbA1c category among 4723 patients with heart failure and diabetes. p = 0.10 for
differences among curves using the log-rank test
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with an even gender mix and high rates of patients
who were uninsured and of racial/ethnic minorities;
studies by Gerstein and Aguilar included more select-
ive subjects who were enrolled in a clinical trial or
were primarily male and insured through the VA, re-
spectively. Nonetheless, we do not believe findings in
our study can be fully explained by racial or ethnic
mix. Although both black and Hispanic patients are
known to have higher levels of HbA1c as compared
to white patients [35–37], HbA1c has been shown to
have a similar relationship for clinical outcomes
among different racial groups [36, 38] and the same
target HbA1c has been recommended for all patients
with diabetes, regardless of race [12].
Our findings should be interpreted in the context
of study limitations. First, inclusion was based on
diagnostic coding algorithms and may be subject to
misclassification despite using validated diagnostic
codes [39, 40]. Second, although the HHC database
contains extensive data on vital signs, inpatient and
outpatient claims, medication utilization and labora-
tory data, it may lack data on several potentially im-
portant variables, including ejection fraction and
functional status. As a result, we were unable to de-
termine of HbA1c had a differential association with
outcomes for patients with heart failure with reduced
versus preserved ejection fraction or patients with
type 1 versus type 2 diabetes. Third, as we were re-
lied on real world EHR data, some of our data may
be subject to misclassification, such as self-reported
race field. Fourth, the data relied on the EHR within
a single hospital system so we may have missed medi-
cation prescriptions and clinical encounters that oc-
curred at another facility. Fifth, as we relied on a
state registry for hospitalization information, we may
have missed some hospitalizations that occurred out
of state. Sixth, the median follow up for mortality
was 658 days. Nonetheless, as the mortality rate was
over 25 % in this study, the null finding of association
between HbA1c and mortality was probably not fully
attributable to low event rate.
Our study had a number of unique strengths. We
included patients from a large public health system
which serves many uninsured and minority patients
in real world practice settings. Such patients are fre-
quently underrepresented in clinical trials [41]. Add-
itionally, we linked our EHR data to state registry
data to obtain complete hospitalization follow up.
This is notable as a large number heart failure related
hospitalizations are hospitals other than where care is
primarily obtained [42].
Conclusions
We found the associated risk of hospitalization in-
creases for HbA1c ≥ 9 %, and not lower HbA1c
values, among patients with heart failure and dia-
betes. The ADA currently recommends targeting an
HbA1c < 7 % for most patients with diabetes but sug-
gests that “less stringent A1c goals (such as < 8 %)
may be appropriate” for subpopulations such as those
with limited life expectancy or significant comorbid-
ity [12]. In support of less stringent glycemic target
for patients with heart failure and diabetes, our data
suggest that there may be a weak threshold effect of
HbA1c above 9 % in this population. Nonetheless,
randomized control trials are needed to determine
the recommended HbA1c for patients with heart failure
and diabetes, who are at high risk of hospitalization
and mortality.
Ethics approval and consent to participate
This study was approved by the NYU School of




Availability of data and materials
Data will not be shared due to restrictions related to
patient confidentiality.
Table 3 Hazard ratio for outcomes of hospitalization, mortality, and heart failure hospitalization by HbA1c category among 4723
patients with heart failure and diabetes. Adjusted for age, sex, race, ethnicity, insurance, comorbidities, blood pressure, heart rate,
creatinine, hemoglobin, medications, and prior utilization
Hospitalization Heart failure hospitalization Mortality
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
HbA1c category
<6.5 1.12 (0.99–1.26) 1.03 (0.90–1.17) 0.95 (0.79–1.14) 0.92 (0.75–1.13) 1.32 (1.10–1.60) 1.16 (0.94–1.42)
6.5–6.9 1.06 (0.93–1.22) 1.05 (0.91–1.22) 0.97 (0.79–1.20) 1.03 (0.83–1.29) 1.09 (0.87–1.35) 1.11 (0.88–1.41)
7–7.9 1.04 (0.93–1.18) 1.03 (0.90–1.17) 1.07 (0.89–1.28) 1.12 (0.93–1.36) 1.03 (0.85–1.25) 1.08 (0.88–1.33)
8–8.9 1 [ref] 1 [ref] 1 [ref] 1 [ref] 1 [ref] 1 [ref]
≥9 1.15 (1.03–1.29) 1.13 (1.00–1.28) 1.31 (1.11–1.55) 1.33 (1.11–1.59) 1.13 (0.94–1.36) 1.20 (0.99–1.45)
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